Nasdaq

Coloplast A/S - Announcement no. 07/2023 – Coloplast announces completion of offering of 12.2 million new B shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA, HONG KONG OR AUSTRALIA, EXCEPT AS ...
Nasdaq

Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new financial ambition towards 2030

In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in ...
Barron's

Coloplast A/S Series B

Coloplast A/S engages in the developing, manufacture, and markets medical products. It operates through the following segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, ...
The Manila Times

Coloplast A/S - Announcement no. 05/2026 - Interim Financial Report, H1 2025/26

Coloplast delivered Q2 organic growth of 6% and 6% EBIT growth1 in constant currencies. Strong quarter in Chronic Care and Interventional Urology, challenging quarter in Wound & Tissue Repair.
Yahoo Finance

Coloplast A/S - Full-Year Financial Results 2023/24

Coloplast delivered Q4 organic growth of 8% and an EBIT margin 1 of 26%, which was negatively impacted by extraordinary costs and currencies. Reported revenue in DKK grew 12% with 3%-pts contribution ...
Seeking Alpha

Coloplast A/S (CLPBF) Q2 2023/2024 Earnings Call Transcript

Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining Coloplast Interim Financial Statements for H1 2023/2024 Conference Call. Throughout today’s recorded presentation ...
Barron's

Coloplast A/S ADR

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
BioWorld

Coloplast’s $2.5B Atos buy gives it a strong voice in laryngectomy market

With its agreement to buy Atos Medical Inc., Coloplast A/S is consolidating its position as a global leader in the chronic care market. Founded in Sweden in 1986, Atos Medical is the largest player ...
Yahoo Finance

Coloplast B A/S (COLO-B.CO) Q2 25/26 earnings call transcript

Earnings call Coloplast delivered 6% organic revenue growth in H1 2025/26, with strong performances in most segments except Wound & Tissue Repair, which saw flat to negative growth and drove revised ...
Finanznachrichten

Coloplast A/S: Coloplast A/S - Coloplast revises financial guidance for FY 2025/26 to reflect reduced growth outlook for Kerecis

Coloplast revises the financial guidance on organic growth and EBIT growth in constant currencies before special items for FY 2025/26, reflecting a slower market recovery in the skin substitutes ...
Seeking Alpha

Coloplast A/S (CLPBF) Q1 2023/2024 Earnings Call Transcript

Good morning. Thank you, operator, and welcome to our Q1 2023/2024 Conference Call. I'm Kristian Villumsen, the CEO of Coloplast; and I'm joined by our CFO, Anders Lonning-Skovgaard; and our Investor ...
Finanznachrichten

Coloplast A/S - Coloplast revises financial guidance for FY 2025/26 to reflect reduced growth outlook for Kerecis

Coloplast revises the financial guidance on organic growth and EBIT growth in constant currencies before special items for FY 2025/26, reflecting a slower market recovery in the skin substitutes ...